7.95
price up icon0.63%   0.05
after-market Dopo l'orario di chiusura: 8.00 0.05 +0.63%
loading

Arvinas Inc Borsa (ARVN) Ultime notizie

pulisher
Jun 18, 2025

Wall Street's Most Accurate Analysts Give Their Take On 3 Health Care Stocks Delivering High-Dividend Yields - Benzinga

Jun 18, 2025
pulisher
Jun 17, 2025

Logos Global Management LP Acquires 4,800,000 Shares in Arvinas Inc - GuruFocus

Jun 17, 2025
pulisher
Jun 17, 2025

Arvinas (NASDAQ:ARVN) Shares Gap UpWhat's Next? - MarketBeat

Jun 17, 2025
pulisher
Jun 17, 2025

Logos Global Management LP Issues a Letter to the Board of Arvinas, Inc. - MarketScreener

Jun 17, 2025
pulisher
Jun 17, 2025

Wall Street Analysts Believe Arvinas (ARVN) Could Rally 89.85%: Here's is How to Trade - MSN

Jun 17, 2025
pulisher
Jun 14, 2025

Arvinas’s SWOT analysis: vepdegestrant efficacy fuels stock potential amid market challenges - Investing.com

Jun 14, 2025
pulisher
Jun 14, 2025

Analysts Set Expectations for Arvinas FY2026 Earnings - MarketBeat

Jun 14, 2025
pulisher
Jun 13, 2025

ARVN: Arvinas' ARV-393 Shows Promise in Preclinical Lymphoma Stu - GuruFocus

Jun 13, 2025
pulisher
Jun 13, 2025

Arvinas Says ARV-393 Preclinical Studies Show 'Significant' Single-Agent Activity in Certain Lymphoma - marketscreener.com

Jun 13, 2025
pulisher
Jun 13, 2025

Arvinas Presents Preclinical Data for PROTAC BCL6 Degrader, ARV- - GuruFocus

Jun 13, 2025
pulisher
Jun 13, 2025

Arvinas Unveils Promising ARV-393 Data at EHA Congress - TipRanks

Jun 13, 2025
pulisher
Jun 13, 2025

Arvinas Presents Preclinical Data for PROTAC BCL6 Degrader, - GlobeNewswire

Jun 13, 2025
pulisher
Jun 13, 2025

Arvinas Presents Preclinical Data for PROTAC BCL6 Degrader, ARV-393, at the European Hematology Association 2025 Congress - GlobeNewswire Inc.

Jun 13, 2025
pulisher
Jun 09, 2025

Wall Street's Most Accurate Analysts Spotlight On 3 Health Care Stocks Delivering High-Dividend Yields - Benzinga

Jun 09, 2025
pulisher
Jun 09, 2025

Arvinas (NASDAQ:ARVN) Stock Price Up 8.7%Here's Why - MarketBeat

Jun 09, 2025
pulisher
Jun 08, 2025

Wedbush Predicts Arvinas' FY2026 Earnings (NASDAQ:ARVN) - MarketBeat

Jun 08, 2025
pulisher
Jun 08, 2025

Wellington Management Group LLP Has $570,000 Stock Position in Arvinas, Inc. (NASDAQ:ARVN) - Defense World

Jun 08, 2025
pulisher
Jun 07, 2025

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Arvinas, Inc.ARVN - WV News

Jun 07, 2025
pulisher
Jun 07, 2025

Leerink Partnrs Has Strong Estimate for Arvinas Q2 Earnings - MarketBeat

Jun 07, 2025
pulisher
Jun 07, 2025

Arvinas (NASDAQ:ARVN) Shares Gap DownHere's Why - MarketBeat

Jun 07, 2025
pulisher
Jun 06, 2025

Arvinas and Pfizer seek FDA approval for breast cancer drug By Investing.com - Investing.com South Africa

Jun 06, 2025
pulisher
Jun 06, 2025

Arvinas (NASDAQ:ARVN) Stock Rating Lowered by Leerink Partnrs - MarketBeat

Jun 06, 2025
pulisher
Jun 06, 2025

Arvinas R&D President Ian Taylor Resigns - TipRanks

Jun 06, 2025
pulisher
Jun 06, 2025

Arvinas (ARVN) and Pfizer Submit NDA for Breast Cancer Treatment - GuruFocus

Jun 06, 2025
pulisher
Jun 06, 2025

Arvinas Announces Submission of New Drug Application to U.S. FDA - GuruFocus

Jun 06, 2025
pulisher
Jun 06, 2025

Will Pfizer Walk Away From Arvinas After PROTAC Disappointment? - insights.citeline.com

Jun 06, 2025
pulisher
Jun 06, 2025

Arvinas (ARVN) and Pfizer Submit FDA Application for Breast Canc - GuruFocus

Jun 06, 2025
pulisher
Jun 06, 2025

Pfizer, Arvinas seek FDA nod for breast cancer therapy (ARVN) - Seeking Alpha

Jun 06, 2025
pulisher
Jun 06, 2025

Arvinas stock rises on FDA submission with Pfizer By Investing.com - Investing.com Nigeria

Jun 06, 2025
pulisher
Jun 06, 2025

Arvinas stock rises on FDA submission with Pfizer - Investing.com Australia

Jun 06, 2025
pulisher
Jun 06, 2025

Arvinas and Pfizer seek FDA approval for breast cancer drug - Investing.com Australia

Jun 06, 2025
pulisher
Jun 06, 2025

Arvinas announces submission of NDA to FDA for vepdegestrant - TipRanks

Jun 06, 2025
pulisher
Jun 06, 2025

Arvinas, Pfizer Submit New Drug Application for Vepdegestrant as Breast Cancer Treatment - marketscreener.com

Jun 06, 2025
pulisher
Jun 06, 2025

Arvinas (ARVN) and Pfizer Submit NDA for Breast Cancer Treatment | ARVN Stock News - GuruFocus

Jun 06, 2025
pulisher
Jun 06, 2025

Arvinas Announces Submission of New Drug Application to U.S. FDA for Vepdegestrant for Patients with ESR1-Mutated ER+/HER2- Advanced or Metastatic Breast Cancer - marketscreener.com

Jun 06, 2025
pulisher
Jun 06, 2025

Arvinas Announces Submission of New Drug Application to - GlobeNewswire

Jun 06, 2025
pulisher
Jun 06, 2025

What is Wedbush’s Forecast for Arvinas FY2026 Earnings? - Defense World

Jun 06, 2025
pulisher
Jun 05, 2025

Q2 Earnings Forecast for Arvinas Issued By Leerink Partnrs - Defense World

Jun 05, 2025
pulisher
Jun 05, 2025

Arvinas to Present Preclinical Data for PROTAC BCL6 Degrader, AR - GuruFocus

Jun 05, 2025
pulisher
Jun 05, 2025

Arvinas to Present Preclinical Data for PROTAC BCL6 Degrader, ARV-393, at the 2025 European Hematology Association (EHA) Annual Meeting | ARVN Stock News - GuruFocus

Jun 05, 2025
pulisher
Jun 05, 2025

Arvinas, Inc. to Present Preclinical Data on ARV-393, an Investigational PROTAC BCL6 Degrader, at EHA Meeting 2025 - Nasdaq

Jun 05, 2025
pulisher
Jun 05, 2025

Arvinas to Present Preclinical Data for PROTAC BCL6 - GlobeNewswire

Jun 05, 2025
pulisher
Jun 05, 2025

Breakthrough PROTAC Technology Shows Efficacy Against 3 Types of Aggressive Lymphoma - Stock Titan

Jun 05, 2025
pulisher
Jun 05, 2025

Arvinas (NASDAQ:ARVN) Earns Market Perform Rating from Leerink Partners - MarketBeat

Jun 05, 2025
pulisher
Jun 05, 2025

Bank of America Corp DE Has $2.47 Million Position in Arvinas, Inc. (NASDAQ:ARVN) - MarketBeat

Jun 05, 2025
pulisher
Jun 03, 2025

H.C. Wainwright reaffirms buy rating on Arvinas stock after trial data - Investing.com Nigeria

Jun 03, 2025
pulisher
Jun 03, 2025

Voloridge Investment Management LLC Buys Shares of 39,063 Arvinas, Inc. (NASDAQ:ARVN) - MarketBeat

Jun 03, 2025
$20.30
price down icon 0.68%
$36.37
price up icon 0.50%
$24.55
price up icon 8.53%
$97.80
price down icon 0.45%
$110.00
price up icon 1.61%
biotechnology ONC
$245.49
price up icon 0.48%
Capitalizzazione:     |  Volume (24 ore):